拓臻生物 内部交易概览
最近18个月交易的高管股东 | 交易次数 | 净买入(股) |
---|---|---|
Seokho Bryan Yoon | 3 | 10,743 |
Mark J. Vignola | 3 | 10,743 |
Senthil Vel Sundaram | 2 | 2,114 |
Vivo Opportunity Fund Holdings, L.p. | 2 | 337,957 |
Orbimed Advisors Llc | 1 | 137,931 |
Carl L Gordon | 1 | 137,931 |
交易分段汇总 | 买入数量 | 卖出数量 | 净买入(股) |
---|---|---|---|
最近1个月 | 0 | 0 | 0 |
最近3个月 | 0 | 420,663 | -420,663 |
最近6个月 | 1,486 | 420,663 | -419,177 |
最近12个月 | 23,591 | 420,663 | -397,072 |
最近18个月 | 1,816,702 | 1,920,663 | -103,961 |
最近36个月 | 3,016,702 | 1,920,663 | 1,096,039 |
拓臻生物 内部交易
拓臻生物 最新内部交易
Vivo Opportunity Fund Holdings, L.p. | 10% Owner | 2024-04-03 | 卖出 | 420,663 | 6,237,329 |
$6.65
|
-6.02%
|
Seokho Bryan Yoon | COO & General Counsel | 2023-11-30 | 买入 | 743 | 18,399 |
$3.78
|
+65.34%
|
Mark J. Vignola | CFO | 2023-11-30 | 买入 | 743 | 18,399 |
$3.78
|
+65.34%
|
Senthil Vel Sundaram | CEO | 2023-05-31 | 买入 | 2,111 | 9,770 |
$1.41
|
+343.26%
|
Mark J. Vignola | CFO | 2023-05-31 | 买入 | 9,997 | 17,656 |
$1.41
|
+343.26%
|
Seokho Bryan Yoon | COO & General Counsel | 2023-05-31 | 买入 | 9,997 | 17,656 |
$1.41
|
+343.26%
|
Hongbo Lu | 董事 | 2022-12-23 | 买入 | 758,620 | 4,340,212 |
$7.25
|
-13.79%
|
Orbimed Advisors Llc | Director, 10% Owner | 2022-12-23 | 买入 | 137,931 | 7,619,135 |
$7.25
|
-13.79%
|
Vivo Opportunity Fund Holdings, L.p. | 10% Owner | 2022-12-23 | 买入 | 758,620 | 6,657,992 |
$7.25
|
-13.79%
|
Carl L Gordon | Director, 10% Owner | 2022-12-23 | 买入 | 137,931 | 7,619,135 |
$7.25
|
-13.79%
|